Seda Yüksel ŞİMŞEK
(Başkent Üniversitesi, Kadın Hastalıkları ve Doğum Kliniği, Adana Dr. Turgut Noyan Uygulama ve Araştırma Merkezi, Adana, Türkiye)
Erhan ŞİMŞEK
(Başkent Üniversitesi, Kadın Hastalıkları ve Doğum Kliniği, Adana Dr. Turgut Noyan Uygulama ve Araştırma Merkezi, Adana, Türkiye)
Selçuk YETKİNEL
(Başkent Üniversitesi, Kadın Hastalıkları ve Doğum Kliniği, Adana Dr. Turgut Noyan Uygulama ve Araştırma Merkezi, Adana, Türkiye)
Songül ALEMDAROĞLU
(Başkent Üniversitesi, Kadın Hastalıkları ve Doğum Kliniği, Adana Dr. Turgut Noyan Uygulama ve Araştırma Merkezi, Adana, Türkiye)
Filiz Aka BOLAT
(Başkent Üniversitesi, Kadın Hastalıkları ve Doğum Kliniği, Adana Dr. Turgut Noyan Uygulama ve Araştırma Merkezi, Adana, Türkiye)
Hüsnü ÇELİK
(Başkent Üniversitesi, Kadın Hastalıkları ve Doğum Kliniği, Adana Dr. Turgut Noyan Uygulama ve Araştırma Merkezi, Adana, Türkiye)
Yıl: 2020Cilt: 21Sayı: 2ISSN: 1309-0399 / 1309-0380Sayfa Aralığı: 102 - 106İngilizce

116 0
Clinicopathologic importance of atypical glandular cells in cervico-vaginal cytology
Objective: To analyze the histopathologic outcomes of patients with atypical glandular cells (AGC) in cervicovaginal cytology examinations.Material and Methods: Patients with AGC in cervicovaginal cytology were included in this study between March 2011 and March 2018 andpatient data were collected retrospectively among all cytology results. AGC classification of cervicovaginal cytology were based on the Bethesda2001 classification system.Results: The total prevalence of cervical epithelial cell abnormality and AGC were found as 4.2% and 0.2%, respectively, in the study cohort.AGC-favor neoplasia (AGC-FN) was the subgroup of AGC with the highest malignancy rate with 62.5% (p=0.06). The incidence of malignancy inthe postmenopausal group (33.3%) was detected higher than in the premenopausal group (8.3%) (p=0.07).Conclusion: The probability of malignancy in AGC-FN cytology is more commonly associated with malignancy in the postmenopausal group.Therefore, histopathologic examination is strongly recommended in these patients with AGC smears because of the high risk for malignancy inthis group. (J Turk Ger Gynecol Assoc 2020; 21: 102-6)
DergiAraştırma MakalesiErişime Açık
  • 1. Wang J, Andrae B, Sundström K, Ström P, Ploner A, Elfström KM, et al. Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study. BMJ 2016; 352:276.
  • 2. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. Gynecol Oncol 2000; 78:97-105.
  • 3. Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer 2005; 103:1258-64.
  • 4. Kim MK, Lee YK, Hong SR, Lim KT. Clinicopathological significance of atypical glandular cells on cervicovaginal Pap smears. Diagn Cytopathol 2017; 45:867-72.
  • 5. Suresh PK, Kini H, Minal J, Dhavalpure N, Basavaiah SH, Adiga DS, et al. The Significance of Glandular Cells on Conventional Cervicovaginal Smears: Experience from a Tertiary Care Hospital in Coastal India. Acta Cytol 2017; 61:199-206.
  • 6. Dunton CJ. Management of Atypical Glandular Cells and Adenocarcinoma in Situ. Obstet Gynecol Clin North Am 2008; 35:623-32.
  • 7. Chin AB, Bristow RE, Korst LM, Walts A, Lagasse LD. The significance of atypical glandular cells on routine cervical cytologic testing in a community-based population. Am J Obstet Gynecol 2000; 182:1278-82.
  • 8. Kumar N, Bongiovanni M, Molliet MJ, Pelte MF, Egger JF, Pache JC. Reclassification and analysis of clinical significance of atypical glandular cells on ThinPrep using Bethesda 2001: Geneva experience. Swiss Med Wkly 2007; 137:635-41.
  • 9. Chhieng DC, Elgert P, Cohen JM, Cangiarella JF. Clinical significance of atypical glandular cells of undetermined significance in postmenopausal women. Cancer 2001; 93:1-7.
  • 10. Tam KF, Cheung AN, Liu KL, Ng TY, Pun TC, Chan YM, et al. A retrospective review on atypical glandular cells of undetermined significance (AGUS) using the Bethesda 2001 classification. Gynecol Oncol 2003; 91:603-7.
  • 11. Haidopoulos DA, Stefanidis K, Rodolakis A, Pilalis A, Symiakaki I, Diakomanolis E. Histologic implications of Pap smears classified as atypical glandular cells. J Reprod Med 2005; 50:539-42. 12. Nayar R, Wilbur DC. The Pap test and Bethesda 2014. Cancer Cytopathol 2015; 123:271-81.
  • 13. Norman I, Hjerpe A, Dillner J. Risk of high-grade lesions after atypical glandular cells in cervical screening: a population-based cohort study. BMJ Open 2017; 7:e017070.
  • 14. Verdoodt F, Jiang X, Williams M, Schnatz PF, Arbyn M. High-risk HPV testing in the management of atypical glandular cells: A systematic review and meta-analysis. Int J Cancer 2016; 138:303-10.
  • 15. Guidelines - ASCCP. http://www.asccp.org/asccp-guidelines. Accessed July 20, 2018.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.